WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and U.S. commercial launch of new versions of its Expro Elite™ and Sympro Elite™ Snares for manipulating interventional devices in peripheral procedures.
Both the Expro Elite™ and Sympro Elite™ Snares represent next-generation versions of the 0.035” interventional snares originally launched in the U.S. in 2008 by Vascular Solutions, now a wholly-owned subsidiary of Teleflex Incorporated.
“We are excited to introduce to the market our enhanced versions of the Expro Elite™ and Sympro Elite™ Interventional Snares, which build on nearly a decade of reliable performance in the cath lab. Both devices feature greatly enhanced pull force for superior handling in challenging procedures,” said Stewart Strong, President and General Manager of the Interventional business unit of Teleflex. “Both snare products feature a durable nitinol construction that retains its shape and adds strength, a radiopaque gold-plated tungsten coil and tip for enhanced visibility, 1:1 torque response for controlled positioning and better access to distal targets, and a unique locking handle that facilitates secure capture.”
The Expro Elite™ Snare uses a helical loop for capture in all directions. The Sympro Elite™ Snare uses a 90-degree loop that remains coaxial to the vessel lumen for easy capture. Both snare products feature a preassembled, one-piece design that allows rapid deployment through any 0.035” compatible lumen. Both the Expro Elite™ and Sympro Elite™ Snares are available in 5, 10, 15, 25, and 35 mm loop diameters for clinical versatility. Both snares are 150 cm in length and are packaged one per box.
Both the Expro Elite™ and Sympro Elite™ Snares are intended for use in the cardiovascular system and hollow viscus to retrieve and/or manipulate objects using minimally-invasive surgical procedures. Manipulation procedures include retrieval and/or repositioning of intravascular foreign objects such as coils, balloons, catheters, and/or guidewires within the cardiovascular system. The devices are not intended for use in the coronary arteries or neurovasculature.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, and Weck® – trusted brands united by a common sense of purpose.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties, and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, Expro Elite, Hudson RCI, LMA, Pilling, Rusch, Sympro Elite and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2018 Teleflex Incorporated. All rights reserved. MC-003826.